Selection of highly transfectable variant from mouse mastocytoma P815.
about
P1343
Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity.Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptideThe gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 miceImmunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutationStructure of the gene of tum- transplantation antigen P35B: presence of a point mutation in the antigenic alleleElicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal modelsInfluence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma."E3/19K" protein of adenovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking cell-surface expression of histocompatibility class I antigens.Site-directed mutagenesis of an HLA-A3 gene identifies amino acid 152 as crucial for major-histocompatibility-complex-restricted and alloreactive cytotoxic-T-lymphocyte recognition.In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcomaExpression of HLA-B27 in transgenic mice is dependent on the mouse H-2D genesRecognition of oligonucleotide-encoded T cell epitopes introduced into a gene unrelated to the original antigen.Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens.Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor.Allele-specific peptide ligand motifs of HLA-C moleculesEpstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP.Tum- antigens, TSTA, and T cell immune surveillance.Stimulation through very late antigen-4 and -5 improves the multifunctionality and memory formation of CD8⁺ T cells.Behavior of the P1.HTR mastocytoma cell line implanted in the chorioallantoic membrane of chick embryos.Alteration of cell responses to PrP(Sc) in prolonged cell culture and its effect on transmission of PrP(Sc) to neural cells.Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cells.A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes.Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo.Transfection of genes for human cell surface antigens identified by monoclonal antibodies.Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecastA nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-EIdentification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein.Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs.Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex.Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice.HER2 peptide-specific CD8(+) T cells are proportionally detectable long after multiple DNA vaccinations.
P2860
Q30769959-838A6EBA-7E55-4465-AC07-199EC37CBC67Q33255829-889E9A25-0FA4-42EB-A270-92C0B24418ACQ33387226-E92BC891-F020-4421-B00B-B49C1D5A2AFDQ33564130-36686F3F-9FFC-40D9-8A33-6322F4301126Q33751018-C794A0EF-78C4-4A7A-AC5A-E58BCF6C9042Q33867634-2FAE83B7-7C62-4599-8C10-1DF56FEB871EQ34577679-C2692514-A145-4E67-B4CA-D762AECA6689Q34601861-0655BA39-0120-4005-93DF-866EFD548A9AQ34640674-521117AA-AB8B-4965-89F1-21B079967882Q34691545-FBFD247D-5AC6-44EE-BCD1-19A70F26BED7Q35159385-BC0DCC1E-7DFB-474D-918C-7FD3F5092606Q36184608-2DB3DDF0-3833-41AD-84A6-48B83648CB11Q36353664-306A8E81-A95F-43AC-B795-EDB5CDFC2271Q36355897-5FBEB94F-4F75-4278-893A-9C591F159551Q36356745-DEB60F3A-D777-4948-AC15-02760279D3CBQ36366282-951C2EBC-4E1A-41E5-B80C-F74993301F1CQ36738644-94B2E70F-D3D9-4F96-891F-653159F2AB92Q36873046-CE1A2B07-849B-424B-A2AA-56F7F2EE80ACQ36968849-2E0F22DA-800A-4C30-8DFC-1D1795418335Q39005255-2CF0B0A1-AD6A-4064-ADC2-7DAB0C39D46BQ39211535-45790124-4F34-4AC2-9B02-626822821779Q39243129-1EACEB9B-2FDA-4C01-8231-0E99839B2572Q39904256-4C07E591-C6C3-41EB-A461-156EB7DBA44AQ40864858-385B63DC-4BF9-4209-BCA0-660F21374D21Q41293978-840532C0-FBB3-447E-880E-3AFFC08D8AA6Q41759110-26985CFD-1800-428B-A0A3-C6906B637E11Q42087769-FEA311E1-1E8D-4FAE-9BB0-FB51F6FF475DQ42603854-6ACF5657-C487-47F7-A5D3-458F81F59119Q42941680-67F95F4A-FE6A-411C-8259-5FA4FA2F833EQ43977140-B73A0A81-D35A-4C73-BAF8-D16D177DE828Q44255903-0065308E-75A9-49C7-96BE-06B410374966Q45790647-7B608CF3-F0BA-45F7-939C-0792687BF37DQ45887207-96CD672F-5FDA-4210-A2E5-08B7BB29EE1A
P2860
Selection of highly transfectable variant from mouse mastocytoma P815.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh-hant
name
Selection of highly transfectable variant from mouse mastocytoma P815.
@en
Selection of highly transfectable variant from mouse mastocytoma P815.
@nl
type
label
Selection of highly transfectable variant from mouse mastocytoma P815.
@en
Selection of highly transfectable variant from mouse mastocytoma P815.
@nl
prefLabel
Selection of highly transfectable variant from mouse mastocytoma P815.
@en
Selection of highly transfectable variant from mouse mastocytoma P815.
@nl
P2093
P356
P1476
Selection of highly transfectable variant from mouse mastocytoma P815.
@en
P2093
P2860
P304
P356
10.1007/BF01534840
P4510
P577
1985-09-01T00:00:00Z